These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 10715308

  • 1. Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and Tirapazamine in Subjects with Advanced Previously Untreated Non-Small-Cell Lung Tumors.
    von Pawel J, von Roemeling R, Gatzemeier U, Boyer M, Elisson LO, Clark P, Talbot D, Rey A, Butler TW, Hirsh V, Olver I, Bergman B, Ayoub J, Richardson G, Dunlop D, Arcenas A, Vescio R, Viallet J, Treat J.
    J Clin Oncol; 2000 Mar; 18(6):1351-9. PubMed ID: 10715308
    [Abstract] [Full Text] [Related]

  • 2. Tirapazamine-cisplatin: the synergy.
    Gatzemeier U, Rodriguez G, Treat J, Miller V, von Roemeling R, Viallet J, Rey A.
    Br J Cancer; 1998 Jun; 77 Suppl 4(Suppl 4):15-7. PubMed ID: 9647615
    [Abstract] [Full Text] [Related]

  • 3. Tirapazamine with cisplatin in patients with advanced non-small-cell lung cancer: a phase II study.
    Treat J, Johnson E, Langer C, Belani C, Haynes B, Greenberg R, Rodriquez R, Drobins P, Miller W, Meehan L, McKeon A, Devin J, von Roemeling R, Viallet J.
    J Clin Oncol; 1998 Nov; 16(11):3524-7. PubMed ID: 9817270
    [Abstract] [Full Text] [Related]

  • 4. Phase II study of the combination of the novel bioreductive agent, tirapazamine, with cisplatin in patients with advanced non-small-cell lung cancer.
    Miller VA, Ng KK, Grant SC, Kindler H, Pizzo B, Heelan RT, von Roemeling R, Kris MG.
    Ann Oncol; 1997 Dec; 8(12):1269-71. PubMed ID: 9496394
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.
    Thatcher N, Hirsch FR, Luft AV, Szczesna A, Ciuleanu TE, Dediu M, Ramlau R, Galiulin RK, Bálint B, Losonczy G, Kazarnowicz A, Park K, Schumann C, Reck M, Depenbrock H, Nanda S, Kruljac-Letunic A, Kurek R, Paz-Ares L, Socinski MA, SQUIRE Investigators.
    Lancet Oncol; 2015 Jul; 16(7):763-74. PubMed ID: 26045340
    [Abstract] [Full Text] [Related]

  • 8. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
    Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, Corral J, Melemed S, John W, Chouaki N, Zimmermann AH, Visseren-Grul C, Gridelli C.
    Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744
    [Abstract] [Full Text] [Related]

  • 9. [Phase II-trial of tirapazamine in combination with cisplatin and gemcitabine in patients with advanced non-small-cell-lung-cancer (NSCLC)].
    Reck M, von Pawel J, Nimmermann C, Groth G, Gatzemeier U.
    Pneumologie; 2004 Dec; 58(12):845-9. PubMed ID: 15597251
    [Abstract] [Full Text] [Related]

  • 10. Concurrent radiochemotherapy with vinorelbine plus cisplatin or carboplatin in patients with locally advanced non-small-cell lung cancer (NSCLC) and an increased risk of treatment complications. Preliminary results.
    Semrau S, Bier A, Thierbach U, Virchow C, Ketterer P, Fietkau R.
    Strahlenther Onkol; 2003 Dec; 179(12):823-31. PubMed ID: 14652671
    [Abstract] [Full Text] [Related]

  • 11. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study.
    Zatloukal P, Petruzelka L, Zemanova M, Havel L, Janku F, Judas L, Kubik A, Krepela E, Fiala P, Pecen L.
    Lung Cancer; 2004 Oct; 46(1):87-98. PubMed ID: 15364136
    [Abstract] [Full Text] [Related]

  • 12. Oral vinorelbine and cisplatin as induction chemotherapy and concomitant chemo-radiotherapy in stage III non-small cell lung cancer: final results of an international phase II trial.
    Krzakowski M, Provencio M, Utracka-Hutka B, Villa E, Codes M, Kuten A, Henke M, Lopez M, Bell D, Biti G, Merimsky O, Beorchia A, Riggi M, Caux NR, Pouget JC, Dubray B, David P.
    J Thorac Oncol; 2008 Sep; 3(9):994-1002. PubMed ID: 18758302
    [Abstract] [Full Text] [Related]

  • 13. Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB/IV non-small-cell lung cancer.
    Yasuda H, Yamaya M, Nakayama K, Sasaki T, Ebihara S, Kanda A, Asada M, Inoue D, Suzuki T, Okazaki T, Takahashi H, Yoshida M, Kaneta T, Ishizawa K, Yamanda S, Tomita N, Yamasaki M, Kikuchi A, Kubo H, Sasaki H.
    J Clin Oncol; 2006 Feb 01; 24(4):688-94. PubMed ID: 16446342
    [Abstract] [Full Text] [Related]

  • 14. Phase I trial of tirapazamine in combination with cisplatin in a single dose every 3 weeks in patients with solid tumors.
    Johnson CA, Kilpatrick D, von Roemeling R, Langer C, Graham MA, Greenslade D, Kennedy G, Keenan E, O'Dwyer PJ.
    J Clin Oncol; 1997 Feb 01; 15(2):773-80. PubMed ID: 9053504
    [Abstract] [Full Text] [Related]

  • 15. Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study.
    Paz-Ares L, Mezger J, Ciuleanu TE, Fischer JR, von Pawel J, Provencio M, Kazarnowicz A, Losonczy G, de Castro G, Szczesna A, Crino L, Reck M, Ramlau R, Ulsperger E, Schumann C, Miziara JE, Lessa ÁE, Dediu M, Bálint B, Depenbrock H, Soldatenkova V, Kurek R, Hirsch FR, Thatcher N, Socinski MA, INSPIRE investigators.
    Lancet Oncol; 2015 Mar 01; 16(3):328-37. PubMed ID: 25701171
    [Abstract] [Full Text] [Related]

  • 16. Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial.
    Shukuya T, Yamanaka T, Seto T, Daga H, Goto K, Saka H, Sugawara S, Takahashi T, Yokota S, Kaneda H, Kawaguchi T, Nagase S, Oguri T, Iwamoto Y, Nishimura T, Hattori Y, Nakagawa K, Nakanishi Y, Yamamoto N, West Japan Oncology Group.
    Lancet Oncol; 2015 Dec 01; 16(16):1630-8. PubMed ID: 26522337
    [Abstract] [Full Text] [Related]

  • 17. Multi-institutional phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer.
    Khuri FR, Rigas JR, Figlin RA, Gralla RJ, Shin DM, Munden R, Fox N, Huyghe MR, Kean Y, Reich SD, Hong WK.
    J Clin Oncol; 2001 May 15; 19(10):2626-37. PubMed ID: 11352954
    [Abstract] [Full Text] [Related]

  • 18. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial.
    Bonomi P, Kim K, Fairclough D, Cella D, Kugler J, Rowinsky E, Jiroutek M, Johnson D.
    J Clin Oncol; 2000 Feb 15; 18(3):623-31. PubMed ID: 10653877
    [Abstract] [Full Text] [Related]

  • 19. Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer.
    Gatzemeier U, von Pawel J, Gottfried M, ten Velde GP, Mattson K, de Marinis F, Harper P, Salvati F, Robinet G, Lucenti A, Bogaerts J, Gallant G.
    J Clin Oncol; 2000 Oct 01; 18(19):3390-9. PubMed ID: 11013280
    [Abstract] [Full Text] [Related]

  • 20. Phase II trial of paclitaxel by 96-hour continuous infusion in combination with cisplatin for patients with advanced non-small cell lung cancer.
    Breathnach OS, Georgiadis MS, Schuler BS, Pizzella P, Llorens V, Kasturi V, Steinberg SM, O'Neil K, Takimoto CH, Johnson BE.
    Clin Cancer Res; 2000 Jul 01; 6(7):2670-6. PubMed ID: 10914708
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.